Protalix Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Protalix Biotherapeutics
PLX Stock  USD 1.69  0.01  0.60%   
Protalix Biotherapeutics financial statements provide useful quarterly and yearly information to potential Protalix Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Protalix Biotherapeutics financial statements helps investors assess Protalix Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Protalix Biotherapeutics' valuation are summarized below:
Gross Profit
28 M
Profit Margin
(0.39)
Market Capitalization
124.4 M
Enterprise Value Revenue
2.2331
Revenue
38.1 M
We have found one hundred twenty available trending fundamental ratios for Protalix Biotherapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protalix Biotherapeutics recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 114.2 M in 2024. Enterprise Value is likely to drop to about 116.7 M in 2024

Protalix Biotherapeutics Total Revenue

68.77 Million

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.8 M, Selling General Administrative of 26.7 M or Other Operating Expenses of 31.5 M, as well as many indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0 or PTB Ratio of 3.4. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Protalix Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets51 M84.4 M68.1 M
Very volatile
Total Current Liabilities47.8 M45.5 M33.9 M
Slightly volatile
Cash31.8 M23.6 M39.8 M
Pretty Stable
Non Current Assets Total9.6 M14.5 M11.8 M
Very volatile
Cash And Short Term Investments33.7 M44.6 M43 M
Pretty Stable
Net Receivables3.1 M5.3 M2.9 M
Slightly volatile
Common Stock Shares Outstanding86.5 M82.4 M25.9 M
Slightly volatile
Liabilities And Stockholders Equity51 M84.4 M68.1 M
Very volatile
Non Current Liabilities Total5.1 M5.3 M52.6 M
Slightly volatile
Other Current Assets1.6 M1.1 M2.2 M
Slightly volatile
Total Liabilities56.1 M50.9 M86.8 M
Very volatile
Total Current Assets42.5 M69.9 M56.3 M
Very volatile
Short and Long Term Debt Total51.9 M26.3 M53.3 M
Pretty Stable
Property Plant And Equipment Net10.5 M10.9 M10.3 M
Pretty Stable
Non Currrent Assets Other501.6 K528 K2.6 M
Slightly volatile
Common Stock Total Equity62.7 K40.2 K73.7 K
Pretty Stable
Other Stockholder Equity435.8 M415 M291.6 M
Slightly volatile
Common Stock62.8 K73 K77.9 K
Pretty Stable
Accounts Payable4.3 M4.3 M5.5 M
Very volatile
Short Term Investments22 M20.9 M7.4 M
Slightly volatile
Other Assets0.951.01.2 M
Pretty Stable
Other Liabilities1.4 M1.5 M21.1 M
Slightly volatile
Property Plant Equipment8.1 M8.7 M9.8 M
Slightly volatile
Current Deferred Revenue2.7 M2.9 M8.2 M
Very volatile
Inventory9.6 M19 M8.8 M
Slightly volatile
Capital Surpluse272 M436 M254.8 M
Slightly volatile
Non Current Liabilities Other43.6 K45.9 K32.1 M
Slightly volatile
Short and Long Term Debt34.9 M18.2 M41.9 M
Slightly volatile
Deferred Long Term Asset Charges101.6 K101.7 K119 K
Slightly volatile
Property Plant And Equipment Gross47.8 M45.6 M18.8 M
Slightly volatile
Long Term Debt Total28.3 M25.4 M41.7 M
Slightly volatile
Cash And Equivalents24.1 M15.4 M38.6 M
Slightly volatile
Capital Stock49.5 K73 K107 K
Slightly volatile
Capital Lease Obligations6.3 M6 M5.7 M
Slightly volatile

Protalix Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative26.7 M25.5 M9.7 M
Slightly volatile
Other Operating Expenses31.5 M55 M45.4 M
Slightly volatile
Total Operating Expenses25 M32.1 M35.4 M
Slightly volatile
Depreciation And Amortization1.7 M1.2 M2 M
Slightly volatile
Total Revenue68.8 M65.5 M32.2 M
Slightly volatile
Gross Profit44.6 M42.5 M20.5 M
Slightly volatile
Cost Of Revenue24.1 M23 M11.6 M
Slightly volatile
Selling And Marketing Expenses42.4 M40.4 M15.4 M
Slightly volatile
Research Development28.1 M17.1 M27 M
Slightly volatile
Extraordinary Items29.6 K33.3 K36.3 K
Slightly volatile
Interest Income686.3 K1.3 M614.1 K
Slightly volatile
Reconciled Depreciation1.1 M1.2 M1.6 M
Slightly volatile

Protalix Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow31 M17.1 M40.5 M
Pretty Stable
End Period Cash Flow31.8 M23.6 M39.8 M
Pretty Stable
Depreciation2 M1.2 M2 M
Slightly volatile
Stock Based Compensation2.3 M3.4 M2.3 M
Pretty Stable
Issuance Of Capital Stock24.9 M24 M40.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.741.834990.4964
Slightly volatile
Days Sales Outstanding27.9129.38136.2122
Slightly volatile
Average Payables45.2 K47.6 K50.2 K
Slightly volatile
Stock Based Compensation To Revenue0.050.05261.6267
Slightly volatile
Capex To Depreciation1.210.96470.6731
Pretty Stable
EV To Sales1.781.875390.2959
Slightly volatile
Inventory Turnover1.151.20673.1904
Slightly volatile
Days Of Inventory On Hand366302452
Very volatile
Payables Turnover5.595.31992.6927
Pretty Stable
Research And Ddevelopement To Revenue0.250.2613.7435
Slightly volatile
Capex To Revenue0.01670.01750.09
Slightly volatile
Cash Per Share0.630.661.3255
Pretty Stable
Days Payables Outstanding65.1868.6102286
Pretty Stable
Current Ratio1.461.5368.2154
Slightly volatile
Receivables Turnover8.0512.42312.0898
Pretty Stable
Graham Number1.111.17365.3861
Pretty Stable
Capex Per Share0.01620.0170.0469
Slightly volatile
Revenue Per Share0.920.97012.1261
Slightly volatile
Interest Debt Per Share0.350.36791.3829
Pretty Stable
Debt To Assets0.490.25650.639
Very volatile
Operating Cycle315332478
Very volatile
Days Of Payables Outstanding65.1868.6102286
Pretty Stable
Quick Ratio1.061.11777.9333
Slightly volatile
Cash Ratio0.490.51912.2136
Slightly volatile
Days Of Inventory Outstanding366302452
Very volatile
Days Of Sales Outstanding27.9129.38136.2122
Slightly volatile
Fixed Asset Turnover6.326.01863.7253
Slightly volatile
Debt Ratio0.490.25650.639
Very volatile
Price Sales Ratio1.741.834990.4964
Slightly volatile
Asset Turnover0.410.77570.5501
Pretty Stable
Gross Profit Margin0.680.64910.5372
Slightly volatile

Protalix Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap114.2 M120.2 M1.1 B
Slightly volatile
Enterprise Value116.7 M122.8 M1.1 B
Slightly volatile

Protalix Fundamental Market Drivers

Forward Price Earnings2.6667
Cash And Short Term Investments44.6 M

Protalix Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.9 M2.7 M
Total Revenue65.5 M68.8 M
Cost Of Revenue23 M24.1 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue(0.33)(0.31)
Research And Ddevelopement To Revenue 0.26  0.25 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.97  0.92 
Ebit Per Revenue 0.16  0.17 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY